Luye Pharma of China to raise $763m in upcoming Hong Kong IPO
This article was originally published in Scrip
Executive Summary
The recent tension between Hong Kong and mainland China has little impact on business. In fact, the Hong Kong market has recently attracted a row of Chinese companies across industries to seek initial public offerings, and one of them is Luye Pharma, a fast growing private pharma based in Yantai, Shandong province.